# Adult Glioma Surgery — GCMD Library living collection

Updated: n/a · 3 episodes · 20 cited statements

## Episodes
### Surgical Strategies
- [Supramaximal Resection in Glioblastoma: Expanding Surgical Boundaries in the Era of Precision Neuro-Oncology-A Systematic Review](https://library.globalcastmd.com/article/supramaximal-resection-in-glioblastoma-expanding-surgical-boundaries-in-the-era-16944) — article · [machine version](https://library.globalcastmd.com/article/supramaximal-resection-in-glioblastoma-expanding-surgical-boundaries-in-the-era-16944.md)

### Molecular Imaging
- [Quantifying T2-FLAIR Mismatch Using Geographically Weighted Regression and Predicting Molecular Status in Lower-Grade Gliomas](https://library.globalcastmd.com/article/quantifying-t2-flair-mismatch-using-geographically-weighted-regression-and-predi-16952) — article · [machine version](https://library.globalcastmd.com/article/quantifying-t2-flair-mismatch-using-geographically-weighted-regression-and-predi-16952.md)

### Liquid Biopsy
- [A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours](https://library.globalcastmd.com/article/a-multi-centre-performance-evaluation-of-a-commercially-developed-liquid-biopsy-16947) — article · [machine version](https://library.globalcastmd.com/article/a-multi-centre-performance-evaluation-of-a-commercially-developed-liquid-biopsy-16947.md)

## Statements
Every statement is attributed, typed, and timestamped; the link is the citation.
- Glioblastoma remains the most aggressive and treatment-resistant primary brain tumor, with patient outcomes strongly associated with the extent of surgical resection. (established) (no timestamp yet)
- Tumor recurrence is largely driven by infiltrating glioma cells that extend beyond the contrast-enhancing margin, which has traditionally served as the boundary for surgical resection. (established) (no timestamp yet)
- Supramaximal resection is defined as surgical resection that extends beyond the contrast-enhancing border. (established) (no timestamp yet)
- The lack of standardized definitions and methodological consistency has limited reproducibility and clinical adoption of supramaximal resection. (open) (no timestamp yet)
- A total of 1045 records were identified, with 37 studies meeting inclusion criteria for this systematic review. (research) (no timestamp yet)
- Supramaximal resection was frequently associated with improved progression-free and overall survival in selected patients, particularly following complete contrast-enhancing tumor resection. (research) (no timestamp yet)
- Two-thirds of brain cancer patients receive their diagnosis only after presenting to the emergency department with more severe symptoms or neurological deficits. (established) (no timestamp yet)
- The EMBRACE study prospectively recruited patients across seven sites in Europe from the United Kingdom, Belgium, Sweden and Switzerland. (research) (no timestamp yet)
- The target population consisted of patients with symptoms potentially associated with brain cancer. (research) (no timestamp yet)
- Test performance was assessed by comparison of the liquid biopsy result to diagnostic imaging. (research) (no timestamp yet)
- 2554 patients were enrolled across the seven collection sites, with 2324 deemed eligible for test assessment. (research) (no timestamp yet)
- There were 697 brain tumours in total, of which 395 were malignant, and 1627 non-tumour diagnoses. (research) (no timestamp yet)
- The Dxcover® Brain Cancer Liquid Biopsy Platform demonstrated 86% sensitivity for brain cancer detection. (research) (no timestamp yet)
- The Dxcover® Brain Cancer Liquid Biopsy Platform demonstrated 99% negative predictive value for brain cancer detection. (research) (no timestamp yet)
- Sensitivity for all brain tumours combined (malignant and benign) was 77%. (research) (no timestamp yet)
- The T2-FLAIR mismatch sign is a validated imaging sign of isocitrate dehydrogenase-mutant 1p/19q noncodeleted gliomas. (established) (no timestamp yet)
- The T2-FLAIR mismatch sign identifies isocitrate dehydrogenase-mutant 1p/19q noncodeleted gliomas with a high positive predictive value. (established) (no timestamp yet)
- Geographically weighted regression can be used to estimate the T2-FLAIR mismatch sign objectively from multiparametric MR imaging scans. (research) (no timestamp yet)
- Statistically significant differences (P value = .05) exist between the averages of residual signatures for isocitrate dehydrogenase-mutant 1p/19q noncodeleted tumors versus other categories. (research) (no timestamp yet)
- The classifier predicts isocitrate dehydrogenase-mutant 1p/19q noncodeleted cases with area under the curve of 0.98 and high specificity and sensitivity. (research) (no timestamp yet)

---
Educational content from recorded physician discussions — not medical advice. Cite the canonical URL or the ?t= deep link. Policy: https://library.globalcastmd.com/ai
